Literature DB >> 24548192

Diagnostic criteria for atypical hemolytic uremic syndrome proposed by the Joint Committee of the Japanese Society of Nephrology and the Japan Pediatric Society.

Toshihiro Sawai1, Masaomi Nangaku, Akira Ashida, Rika Fujimaru, Hiroshi Hataya, Yoshihiko Hidaka, Shinya Kaname, Hirokazu Okada, Waichi Sato, Takashi Yasuda, Yoko Yoshida, Yoshihiro Fujimura, Motoshi Hattori, Shoji Kagami.   

Abstract

Atypical hemolytic uremic syndrome (aHUS) is rare and comprises the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. Recently, abnormalities in the mechanisms underlying complement regulation have been focused upon as causes of aHUS. The prognosis for patients who present with aHUS is very poor, with the first aHUS attack being associated with a mortality rate of approximately 25%, and with approximately 50% of cases resulting in end-stage renal disease requiring dialysis. If treatment is delayed, there is a high risk of this syndrome progressing to renal failure. Therefore, we have developed diagnostic criteria for aHUS to enable its early diagnosis and to facilitate the timely initiation of appropriate treatment. We hope these diagnostic criteria will be disseminated to as many clinicians as possible and that they will be used widely.
© 2014 Japan Pediatric Society and Japanese Society of Nephrology.

Entities:  

Keywords:  ADAMTS13; alternative complement pathway; atypical hemolytic uremic syndrome; complement dysregulation; thrombotic microangiopathy

Mesh:

Year:  2014        PMID: 24548192     DOI: 10.1111/ped.12274

Source DB:  PubMed          Journal:  Pediatr Int        ISSN: 1328-8067            Impact factor:   1.524


  6 in total

1.  Three months interval therapy of Eculizumab in a patient with atypical hemolytic uremic syndrome with hybrid CFHR1/CFH gene.

Authors:  Sami Alobaidi; Ammar AlDabbagh; Amany Alamoudi; Murad Almowarey; Ahmed Akl
Journal:  CEN Case Rep       Date:  2019-02-04

2.  Clinical guides for atypical hemolytic uremic syndrome in Japan.

Authors:  Hideki Kato; Masaomi Nangaku; Hiroshi Hataya; Toshihiro Sawai; Akira Ashida; Rika Fujimaru; Yoshihiko Hidaka; Shinya Kaname; Shoichi Maruyama; Takashi Yasuda; Yoko Yoshida; Shuichi Ito; Motoshi Hattori; Yoshitaka Miyakawa; Yoshihiro Fujimura; Hirokazu Okada; Shoji Kagami
Journal:  Clin Exp Nephrol       Date:  2016-08       Impact factor: 2.801

3.  Hemolytic uremic syndrome in a developing country: Consensus guidelines.

Authors:  Arvind Bagga; Priyanka Khandelwal; Kirtisudha Mishra; Ranjeet Thergaonkar; Anil Vasudevan; Jyoti Sharma; Saroj Kumar Patnaik; Aditi Sinha; Sidharth Sethi; Pankaj Hari; Marie-Agnes Dragon-Durey
Journal:  Pediatr Nephrol       Date:  2019-04-15       Impact factor: 3.714

4.  Clinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in Korea.

Authors:  Hae Il Cheong; Sang Kyung Jo; Sung Soo Yoon; Heeyeon Cho; Jin Seok Kim; Young Ok Kim; Ja Ryong Koo; Yong Park; Young Seo Park; Jae Il Shin; Kee Hwan Yoo; Doyeun Oh
Journal:  J Korean Med Sci       Date:  2016-10       Impact factor: 2.153

5.  Atypical hemolytic uremic syndrome precipitated by thyrotoxicosis: a case report.

Authors:  Ling Hou; Yue Du
Journal:  BMC Pediatr       Date:  2020-04-17       Impact factor: 2.125

Review 6.  Pediatric Atypical Hemolytic Uremic Syndrome Advances.

Authors:  Rupesh Raina; Nina Vijayvargiya; Amrit Khooblall; Manasa Melachuri; Shweta Deshpande; Divya Sharma; Kashin Mathur; Manav Arora; Sidharth Kumar Sethi; Sonia Sandhu
Journal:  Cells       Date:  2021-12-18       Impact factor: 7.666

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.